Use of NAC in Alleviation of Hangover Symptoms

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This will be a double-blinded study involving healthy non-alcoholic (self-reported) volunteers over the age of 21 to consume beer on hospital property in a safe environment to ensure immediate availability to medical attention and to security if needed. Volunteers will be recruited from residency programs, hospital employees, emergency medical personnel, and friends of study investigators. The volunteers will drink to a BAC of 0.1 as checked with a breathalyzer. They will wear a tag around their neck with their study number, which will be hole-punched with every beer consumed, which will be collected at the end of the night for an accurate count of beers consumed per person. They however will not be forced to drink anymore if they are uncomfortable with the amount of alcohol they are consuming and can withdraw from the study at any time. All participants will be required to be driven home by a sober driver once the participant's BAT is 0.02 or less. At the end of the night, the volunteer will be breathalyzed to determine BAC, and given 1 capsule per 3 drinks consumed of either 600 mg N-Acetyl-L-Cysteine or placebo capsules. In the morning, each participate will fill out a Hangover Symptom Score questionnaire, evaluating each hangover symptom on a 0 - 4 point Hangover Symptom Severity scale. A random number generator will be used to determine Placebo or NAC first, then the participant will be given the other treatment at their subsequent encounter. The study will be conducted over the series of many months, and data can be analyzed by self-control comparing the participant's hangover symptom severity as determined by the hangover symptom scale data when using NAC compared to placebo. The data will be analyzed using the numerical values of each category for hangover classification and compare the placebo data to the control data.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use of NAC in Prevention of Hangover Symptoms; Independent Alcohol Consumption Protocol

NCT03104959

Prevention of Hangover Using N-Acety Cysteine

TERMINATED NA

Signatures of N-Ac for Non-Suicidal Self-Injury in Adolescents

NCT04005053

Self-Harm Depression Suicide

COMPLETED PHASE2

L-cysteine Prevents Stomach Exposure to Carcinogenic Acetaldehyde

NCT02524262

Gastritis, Atrophic

COMPLETED PHASE2

Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

NCT04542161

Chronic Fatigue Syndrome Myalgic Encephalomyelitis

RECRUITING PHASE2

The Effect of N- Acetylcysteine on Inflammatory and Oxidative Stress Biomarkers

NCT02420418

Bipolar Disorder

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hangover Symptoms, NAC

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NAC group

Patients receiving NAC after drinking to breathalyzer value 0.1

Group Type ACTIVE_COMPARATOR

N Acetyl Cysteine

Intervention Type DIETARY_SUPPLEMENT

Placebo group

Patients receiving placebo after drinking to breathalyzer value 0.1

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

N Acetyl Cysteine

Intervention Type DIETARY_SUPPLEMENT

placebo

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NAC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy volunteers over age 21 years

Exclusion Criteria

* Volunteers will be excluded from the study if they suffer from any of the following conditions:
* Alcoholism,
* Pregnancy,
* Reactive Airway Disease,
* Diabetes,
* Kidney or bladder stones,
* Kidney disease,
* Liver disease,
* Stomach ulcer,
* Organ transplant patients,
* Dialysis patients,
* and patients with alcohol, egg, milk or wheat allergies.

Volunteers taking the following medications will not be able to participate:

* activated charcoal,
* ampicillin,
* carbamazepine,
* cephaloridine,
* cloxacillin,
* methicillin,
* nitroglycerine,
* oxacillin,
* penicillin G,
* or quinacillin.

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes